In the first half of 2025, China’s innovative drug license-out deals surpassed USD 15 billion, marking a 40% year-over-year increase. Antibody-drug conjugates (ADCs) and bispecific antibodies now account for over 60% of all outbound transactions — signaling a new wave of China’s pharmaceutical globalization. According to DengYueMed’s Top 10 China Pharma Deals 2025, a global … Continue reading Top 10 China Pharma Deals 2025: $40B in Global Innovation Exports